Multimodality imaging of IL-18-binding protein-Fc therapy of experimental lung metastasis

Clinical Cancer Research

Volumn 14, Issue 19, 2008, Pages 6137-6145

  Cao, Qizhen ^a   Cai, Weibo ^a,b   Niu, Gang ^a   He, Lina ^a   Chen, Xiaoyuan ^a  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID INTERLEUKIN 18 BINDING PROTEIN IMMUNOGLOBULIN FC FRAGMENT CU 64; FLUORODEOXYGLUCOSE F 18; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; INTERLEUKIN 18; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 18 BINDING PROTEIN IMMUNOGLOBULIN FC FRAGMENT; INTERLEUKIN 18 RECEPTOR; INTERLEUKIN 1BETA CONVERTING ENZYME; LUCIFERASE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; INTERLEUKIN-18 BINDING PROTEIN; SIGNAL PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; BIOLOGICAL MONITORING; BIOLUMINESCENCE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER MODEL; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; GENETIC TRANSFECTION; LUNG METASTASIS; LUNG WEIGHT; METASTASIS INHIBITION; MICRO-COMPUTED TOMOGRAPHY; MOLECULAR IMAGING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT OUTCOME; ANIMAL; BREAST TUMOR; CANCER TRANSPLANTATION; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; EXPERIMENTAL MELANOMA; IMMUNOTHERAPY; LUNG TUMOR; METABOLISM; METASTASIS; METHODOLOGY; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOTHERAPY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-18; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 58149144780     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0049     Document Type: Article

References (40)

1. Ghayur T, Banerjee S, Hugunin M, et al. Caspase-1 processes IFN-γ-inducing factor and regulates LPS-induced IFN-γ production. Nature 1997;386:619-23.
2. Dinarello CA. Interleukin-18 and the pathogenesis of inflammatory diseases. Semin Nephrol 2007;27:98-114.
3. Reddy P. Interleukin-18: recent advances. Curr Opin Hematol 2004;11:405-10.
4. Sergi B, Penttila I. Interleukin 18 receptor. J Biol Regul Homeost Agents 2004;18:55-61.
5. Eissa SA, Zaki SA, El-Maghraby SM, Kadry DY. Importance of serum IL-18 and RANTES as markers for breast carcinoma progression. J Egypt Natl Cancer Inst 2005;17:51-5.
6. Gunel N, Coskun U, Sancak B, et al. Prognostic value of serum IL-18 and nitric oxide activity in breast cancer patients at operable stage. Am J Clin Oncol 2003;26:416-21.
7. Tsuboi K, Miyazaki T, Nakajima M, et al. Serum interleukin-12 and interleukin-18 levels as a tumor marker in patients with esophageal carcinoma. Cancer Lett 2004;205:207-14.
8. Vidal-Vanaclocha F, Mendoza L, Telleria N, et al. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression. Cancer Metastasis Rev 2006;25:417-34.
9. Osaki T, Hashimoto W, Gambotto A, et al. Potent antitumor effects mediated by local expression of the mature form of the interferon-γ inducing factor, interleukin-18 (IL-18). Gene Ther 1999;6:808-15.
10. Ju DW, Tao Q, Lou G, et al. Interleukin 18 transfection enhances antitumor immunity induced by dendritic cell-tumor cell conjugates. Cancer Res 2001;61:3735-40.
11. Tatsumi T, Gambotto A, Robbins PD, Storkus WJ. Interleukin 18 gene transfer expands the repertoire of antitumor Th1-type immunity elicited by dendritic cell-based vaccines in association with enhanced therapeutic efficacy. Cancer Res 2002;62:5853-8.
12. Vidal-Vanaclocha F, Fantuzzi G, Mendoza L, et al. IL-18 regulates IL-1β-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc Natl Acad Sci U S A 2000;97:734-9.
13. Cho D, Song H, Kim YM, et al. Endogenous interleukin-18 modulates immune escape of murine melanoma cells by regulating the expression of Fas ligand and reactive oxygen intermediates. Cancer Res 2000;60:2703-9.
14. Park CC, Morel JC, Amin MA, Connors MA, Harlow LA, Koch AE. Evidence of IL-18 as a novel angiogenic mediator. J Immunol 2001;167:1644-53.
15. Dinarello CA. Targeting interleukin 18 with interleukin 18 binding protein. Ann Rheum Dis 2000;59 Suppl 1:i17-20.
16. Faggioni R, Cattley RC, Guo J, et al. IL-18-binding protein protects against lipopolysaccharide-induced lethality and prevents the development of Fas/Fas ligand-mediated models of liver disease in mice. J Immunol 2001;167:5913-20.
17. Sivakumar PV, Westrich GM, Kanaly S, et al. Interleukin 18 is a primary mediator of the inflammation associated with dextran sulphate sodium induced colitis: blocking interleukin 18 attenuates intestinal damage. Gut 2002;50:812-20.
18. Nicoletti F, Di Marco R, Papaccio G, et al. Essential pathogenic role of endogenous IL-18 in murine diabetes induced by multiple low doses of streptozotocin. Prevention of hyperglycemia and insulitis by a recombinant IL-18-binding protein: Fc construct. Eur J Immunol 2003;33:2278-86.
19. Mankoff DA. A definition of molecular imaging. J Nucl Med 2007;48:18N, 21N.
20. Cherry SR, Shao Y, Silverman RW, et al. MicroPET: a high resolution PET scanner for imaging small animals. IEEE Trans Nucl Sci 1997;44:1161-6.
21. Paulus MJ, Gleason SS, Kennel SJ, Hunsicker PR, Johnson DK. High resolution X-ray computed tomography: an emerging tool for small animal cancer research. Neoplasia 2000;2:62-70.
22. Hwang JY, Moffatt-Blue C, Equils O, et al. Multimode optical imaging of small animals: development and applications. Proc SPIE 2007;6441:644105/1-/10.
23. Cai W, Rao J, Gambhir SS, Chen X. How molecular imaging is speeding up anti-angiogenic drug development. Mol Cancer Ther 2006;5:2624-33.
24. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 2003;17:545-80.
25. Cai W, Chen K, Mohamedali KA, et al. PET of vascular endothelial growth factor receptor expression. J Nucl Med 2006;47:2048-56.
26. Cai W, Wu Y, Chen K, Cao Q, Tice DA, Chen X. In vitro and in vivo characterization of 64 Cu-labeled AbegrinTM, a humanized monoclonal antibody against integrin avb3. Cancer Res 2006;66:9673-81.
27. Cai W, Ebrahimnejad A, Chen K, et al. Quantitative radioimmuno PET imaging of EphA2 in tumour-bearing mice. Eur J Nucl Med Mol Imaging 2007;34:2024-36.
28. Cai W, Olafsen T, Zhang X, et al. PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. J Nucl Med 2007;48:304-10.
29. Randle JC, Harding MW, Ku G, Schonharting M, Kurrle R. ICE/Caspase-1 inhibitors as novel antiinflammatory drugs. Expert Opin Investig Drugs 2001;10:1207-9.
30. Siegmund B. Interleukin-1β converting enzyme (caspase-1) in intestinal inflammation. Biochem Pharmacol 2002;64:1-8.
31. Jenkins DE, Oei Y, Hornig YS, et al. Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis. Clin Exp Metastasis 2003;20:733-44.
32. Szentirmai O, Baker CH, Lin N, et al. Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect. Neurosurgery 2006;58:365-72.
33. Hsu AR, Hou LC, Veeravagu A, Tse V, Chen X. In vivo near-infrared fluorescence imaging of integrin avb3 in an orthotopic glioblastoma model. Mol Imaging Biol 2006;8:315-23.
34. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42:1-93S.
35. Frese KK, Tuveson DA. Maximizing mouse cancer models. Nat Rev Cancer 2007;7:645-58.
36. Weigelt B, Peterse JL, van 't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005;5:591-602.
37. Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer 2006;6:449-58.
38. Gwyther SJ. New imaging techniques in cancer management. Ann Oncol 2005;16 Suppl 2:ii63-70.
39. Rudin M, Weissleder R. Molecular imaging in drug discovery and development. Nat Rev Drug Discov 2003;2:123-31.
40. Carrascal MT, Mendoza L, Valcárcel M, et al. Interleukin-18 binding protein reduces b16 melanoma hepatic metastasis by neutralizing adhesiveness and growth factors of sinusoidal endothelium. Cancer Res 2003;63:491-7.